Adviezen commissie BOM

Terug naar lijst
  • Auteur
  • NVMO-commissie BOM
  • Printdatum
  • 14-12-2005
  • E-pubdatum
  • 10-04-2014
  • Bron
  • Medische Oncologie

Epoëtine bij milde anemie door chemotherapie

Behandeling met epoëtine kan naast het geven van bloedtransfusies worden overwogen bij een behandeling met chemotherapie en anemiegerelateerde klachten als het Hb-gehalte lager is dan 6,2 mmol/l.


  1. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-14. 
  2. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematological parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74.
  3. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidencebased clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-107.
  4. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer. Eur J Cancer 2004;40:2201-16.
  5. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-17.
  6. Chang J, Couture F, Young S, et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23:2597-605.
  7. Browman GP. Standards of proof, standards of practice, and proof of standards: a tale of two trials. J Clin Oncol 2005;23:2583-5.
  8. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
  9. Steensma DP, Loprinzi CL. Erythropoietin use in cancer patients: a matter of life and death? J Clin Oncol 2005;23:5865-8.
  10. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-98.
  11. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebocontrolled trial. Lancet 2003;362:1255-60.